This National Psoriasis Foundation primer, published in JAMA Dermatology, provides dermatologists and rheumatologists with a practical framework for understanding GLP-1 RA pharmacology, their landmark cardiovascular, metabolic, and organ-protection trial data, the emerging evidence base for psoriasis-specific benefit, and a clinical guide to agent selection, dosing, and safety monitoring in patients with psoriasis
These can include: Ondansetron (Zofran): An effective antiemetic often prescribed for various types of nausea and vomiting
In research and clinical settings, HRV is typically derived from highly controlled ECG recordings
Even at low doses, GLP-1 medications carry a risk of serious side effects, such as acute pancreatitis or gallbladder disorders